No profile data available.
Regnum Corp. (RGMP) is a consumer-oriented services company in the additional content distribution services industry, based in New York, United States, with about 1 full-time employees.
It reported revenue of $0 for fiscal year 2022, and net income of -$780,887. In Q1 2023 (the quarter ended March 31, 2023) revenue was $0. Its market capitalization was $2,295 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2022; market data as of October 8, 2026.
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.
Regnum reported $0 in revenue for fiscal year 2022. In Q1 2023 revenue was $0.
$2,295 as of October 8, 2026.
Listed companies of a similar size in the same industry (additional content distribution services) include Chicken Soup for the Soul Entertainment, Inc. (CSSEQ), Uomo Media Inc. (UOMO), Tix Corporation (TIXC), Spotlight Capital Holdings, Inc. (SLCH).